NKCx Histopathological outcome* within 12 months after cervix cytology in 2024
Country Total

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 2463 9.4% 1174 4.5% 424 1.6% 19 0.1% 6 0.0% 53 0.2% 22137 84.2% 26276 100.0%
ASCUS 4920 38.1% 3682 28.5% 1786 13.8% 39 0.3% 19 0.1% 155 1.2% 2315 17.9% 12916 100.0%
LSIL 2168 29.2% 2471 33.3% 1364 18.4% 2 0.0% 8 0.1% 82 1.1% 1335 18.0% 7430 100.0%
Atypical glandular cells/AGC 47 30.9% 19 12.5% 31 20.4% 35 23.0% 9 5.9% 2 1.3% 9 5.9% 152 100.0%
Unclear atypia 240 47.2% 132 26.0% 75 14.8% 13 2.6% 4 0.8% 3 0.6% 41 8.1% 508 100.0%
ASC-H 202 15.7% 288 22.4% 705 54.8% 22 1.7% 25 1.9% 7 0.5% 38 3.0% 1287 100.0%
HSIL 96 6.8% 136 9.6% 1054 74.3% 26 1.8% 45 3.2% 10 0.7% 51 3.6% 1418 100.0%
Suspected Adenocarcinom 2 6.7% 1 3.3% 3 10.0% 7 23.3% 6 20.0% . . 11 36.7% 30 100.0%
Squamous cell cancer 2 5.4% . . 17 45.9% . . 15 40.5% . . 3 8.1% 37 100.0%
Totalt 10140 20.3% 7903 15.8% 5459 10.9% 163 0.3% 137 0.3% 312 0.6% 25940 51.8% 50054 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the category Cancer:
M80703, M81403, M83803, M84416, M84613